Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
TVTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.12 - $25.29
Previous CloseN/A
Volume140.04K
Average Volume (3M)1.61M
Market Cap
$1.99B
Enterprise Value$1.21B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Feb 20, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding87,034,300
10 Day Avg. Volume2,319,083
30 Day Avg. Volume1,612,523
Standard Deviation0.18
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.79
Price to Cash Flow (P/CF)-10.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.07
Enterprise Value/Ebitda-4.12
Forecast
1Y Price Target
$33.18Price Target Upside42.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's pre-reported Q4 Filspari revenue is $50MM, indicating strong performance.
Market PotentialThe probability of success estimate for sparsentan in FSGS has increased from a prior 20% to 75%.
Regulatory ApprovalTravere is moving ahead with an sNDA filing for Filspari in FSGS, which represents another $1.0B+ opportunity.
Bears Say
Competitive LandscapeThe launch in FSGS could surpass that of IgAN, given the high unmet need and urgency for treatment.
Market ExpectationsThe FSGS opportunity for Filspari is not fully factored in yet, with recent analyses suggesting a regulatory path forward and potential for significant future revenue.
Revenue ForecastThe 2025 Filspari estimate has been increased to $210MM, reflecting steady new patient growth.
---
Ownership Overview
1.49% Insiders
21.14% Mutual Funds
44.12% Other Institutional Investors
17.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $5.12 and its highest was $25.29 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $1.99B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is today.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Oct 31, 2024. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.669 by -$0.031.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -0.56.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 87,034,300 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.669. Following the earnings report the stock price went down -1.464%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in TVTX
---
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.18 (42.22% Upside)
$33.18 (42.22% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.34%
12-Months-Change
Fundamentals
Return on Equity
-279.94%
Trailing 12-Months
Asset Growth
-39.44%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics is focused on developing therapies for rare kidney and metabolic disorders. The biopharmaceutical company's products include FILSPARI (sparsentan), and Thiola and Thiola EC (tiopronin tablets).
---
TVTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook for Travere Therapeutics, with significant advancements in the approval and market expansion of FILSPARI, strong financial growth, and promising regulatory progress for FSGS. However, challenges remain with the pause in pegtibatinase enrollment and reported net loss.Read More>---
TVTX Stock 12 Month Forecast
Average Price Target
$33.18
▲(42.22% Upside)
Technical Analysis
Amgen
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering TVTX
1 Year
1 Year Success Rate
17/26 ratings generated profit
1 Year Average Return
+26.08%
reiterated a buy rating 9 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 65.38% of your transactions generating a profit, with an average return of +26.08% per trade.
---